GHK-Cu

Main evidence: Human clinical trials. Updated 2026-10-28.

What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.

Summary

This pack summarizes topical human research, reported injection practices, safety caveats and Australian regulatory context for GHK-Cu.

What the sources say

GHK-Cu is a copper-bound complex of the naturally occurring peptide GHK; the dated review summarizes topical human skin studies and does not establish effects from injection. (Human clinical trials; Pickart L, Vasquez-Soltero JM, Margolina A., "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration", 2015-07-07)
Injectable dosing, mixing and storage claims in the source pack are clinic/vendor conventions, not a validated human injection protocol. (Community reports; Beverly Hills Rejuvenation Center, "GHK-Cu Dosage & Injection Protocol Guide: Reconstitution, Chart & Cycling", 2026-09-11)
An ongoing registered study is evaluating topical GHK-Cu gel for acute wounds; the registry reports no results posted. Registration is not evidence of efficacy. (Educator material (not peer reviewed); ClinicalTrials.gov, NCT07437586, topical GHK-Cu gel wound study, 2026-02-27)
Small placebo-controlled topical studies summarized in the dated review reported changes in photoaged skin measures such as laxity, clarity, firmness, fine lines and skin density over about 12 weeks; studies were small and often industry- or discoverer-linked. (Human clinical trials; Pickart L, Vasquez-Soltero JM, Margolina A., "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration", 2015-07-07)
A topical thigh-skin comparison reported collagen production in 70% of GHK-Cu participants, 50% with vitamin C cream and 40% with retinoic acid; this does not establish benefit from injection or from combining those products. (Human clinical trials; Pickart L, Vasquez-Soltero JM, Margolina A., "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration", 2015-07-07)
Clinicians interviewed by NPR described caution about injection without human safety and efficacy studies; some reported topical products worked better than injections in their own practice. These are expert/practice observations, not controlled comparisons. (Educator material (not peer reviewed); NPR, "People are injecting copper peptides ahead of the science", 2026-09-07)
The dated review focuses on topical skin evidence; it does not establish human benefits of injected GHK-Cu for hair growth, wounds or systemic anti-ageing. (Educator material (not peer reviewed); Pickart L, Vasquez-Soltero JM, Margolina A., "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration", 2015-07-07)
The dated review describes small topical studies without major short-term safety problems; these results do not establish safety for injectable GHK-Cu. (Human clinical trials; Pickart L, Vasquez-Soltero JM, Margolina A., "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration", 2015-07-07)
A dated news report quotes clinicians and dermatologists cautioning against injection in the absence of published human safety and efficacy studies; this is an evidence gap, not proof that injection caused harm. (Educator material (not peer reviewed); NPR, "People are injecting copper peptides ahead of the science", 2026-09-07)
The TGA/Chief Medical Officer warns generally that unapproved peptide products may have uncertain composition and sterility and have been associated with liver damage, severe allergic reactions and inflammation; the warning does not assign each event specifically to GHK-Cu. (Educator material (not peer reviewed); TGA and Chief Medical Officer, "Concerns regarding the public health risks associated with unapproved peptide products", 2026-06-19)
The TGA/Chief Medical Officer warning names GHK-Cu among unapproved peptide products not assessed for safety, quality or effectiveness in Australia and strongly advises against purchase or use, particularly online or from overseas. (Educator material (not peer reviewed); TGA and Chief Medical Officer, "Concerns regarding the public health risks associated with unapproved peptide products", 2026-06-19)
The TGA/Chief Medical Officer warning names GHK-Cu among unapproved peptide products; it does not classify every topical cosmetic formulation, and it does not authorize injectable use. (Educator material (not peer reviewed); TGA and Chief Medical Officer, "Concerns regarding the public health risks associated with unapproved peptide products", 2026-06-19)
The 2026 WADA Prohibited List is the relevant anti-doping reference, but the dated material here does not establish a specific GHK-Cu classification; athletes should verify the current status with anti-doping authorities. (Educator material (not peer reviewed); World Anti-Doping Agency, 2026 Prohibited List, 2026-01-01)

Sources

Dosing, stacking and protocol details are not published here.